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Evaluation of the Potential HMGA1-EF24 Nexus in Human Colon
Cancer
Madeline Diaz
Takita Sumter, Ph.D. (Mentor)
ABSTRACT
The architectural chromatin binding proteins High Mobility Group A1 (HMGA1) are proteins
expressed at high levels in malignant cancers and induce neoplastic transformation. The protein is
increased as the last step of the Wnt/-catenin/TCF-4 pathway and mediates drug resistance,
therefore correlating with a poor patient prognosis. HMGA1-mediated chemoresistance results from
a self-protective process called cellular senescence. Analogs of the antioxidant, curcumin, when used
in combination with traditional chemotherapeutic agents, are useful treatment options for drug
resistant tumors. This study had two specific aims. The first being to investigate how colon cancer
cells HCT116 respond to treatment with EF24. The second aim was to evaluate how hmga1
expression changed as a result of treatment with EF24. Our preliminary findings showed that cell
viability decreased after 24-hour treatment with low-dose EF24, as indicated by an MTS assay, with
notable discrepancies between cells that underwent a pulsed treatment regimen versus those that
underwent continuous treatment. Furthermore, we demonstrated that cells exhibited fragmented
DNA when treated with low-dose EF24, which is characteristic of apoptotic cells. At higher, pulsed
doses, senescence activity increased, indicating the induction of a senescence pathway. Lastly, gene
expression studies indicated that hmga1 was significantly down regulated in cells treated with
continuous, low-dose EF24. Further investigation of this pathway could lead to decreased toxicity
and increased viability of combination cancer therapies.
Hmga1 was identified as a gene that is
induced by growth factors, and is required by
cells to pass through the G1/S cell cycle
checkpoint (Fedele et al., 2001). More
importantly, HMGA1 functions as an oncogene
when overexpressed in those same cells (Resar,
2010). Therefore, it follows that hmga1 is upregulated in a number of malignant cancers
including, but not limited to: ovarian, breast,
lung, thyroid, and colon cancers (Scala et al.,
2000). When tissue samples from normal,
unaffected mice were compared to their
metastatic counterparts, the HMGA1 levels
were almost undetectable; suggesting that
HMGA1 plays an important role in the
transformation of cells from normal to
malignant (Xu et al., 2004). Furthermore, when
compared to localized tumors, hmga1 was vastly
up-regulated in the metastatic counterparts.
Similarly, malignant tissues in which hmga1 is
overexpressed exhibit increased resistance to
common chemotherapeutic drugs. When hmga1
expression is inhibited, sensitivity to the same

INTRODUCTION
The High Mobility Group A1
(HMGA1) family of proteins are non-histone
binding architectural proteins. They are aptly
named based on their high mobility in
polyacrylamide gel (Reeves, 2001). The subfamily consists of two isoforms, HMGA1a and
HMGA1b, which are the result of alternately
spliced mRNA transcripts derived from the
common hmga1 gene. The HMGA1 proteins are
characterized by a prominent binding domain
that preferentially binds to AT-rich regions on
the minor groove of DNA (Reeves, 2001). This
allows the protein to alter shape of B-form
DNA and control the transcription of a variety
of genes and the activity of a variety of proteins
(Thanos et al., 1992). Depending on the context,
HMGA1 can promote or repress a variety of
molecular pathways. As a result, the HMGA
family participates in a number of cellular
processes including cellular proliferation,
neoplastic transformation, aging and metastasis
(Reeves, 2001).
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drugs increased significantly (D’Angelo et al.,
2014). Taken together, these factors suggest that
there is a correlation between high levels of
hmga1 expression and poor patient prognosis.
When a malignant cell undergoes
therapeutic treatment, it triggers a number of
responses; the two most prominent responses
are apoptosis and a protective cellular process
known as senescence (Childs et al., 2014).
Previous research shows that HMGA1 disrupts
normal cell cycle regulation by preventing
malignant cells from undergoing apoptosis
while simultaneously propelling it through
mitosis (Fedele et al., 2001). Contrastingly,
HMGA1 also promotes cellular senescence
(Narita et al, 2006). Senescence is characterized
by arrest of the cell cycle, expression of SA-galactosidase and induction of tumor
suppressors p16 and p21. Senescent cells can
then induce a change in phenotype in
surrounding cells through emission of an
intercellular signal (Narita et al, 2006).
Curcumin, the active ingredient of the
turmeric plant, possesses novel antioxidant,
anti-inflammatory
and
anti-proliferative
properties. Studies show that malignant tissues
treated with curcumin exhibited elevated levels
of HMGA1 and subsequently induced apoptosis
and senescence (Kuo et al., 1996; Jin et al., 2016
and Mosieniak et al., 2016). However, a clinical
study showed that curcumin presents with low
bio-availability (Ramasamy et al., 2015 and
Cheng et al., 2001). EF24 is a chemically
synthesized analog of curcumin, however its
exact anti-proliferative mechanism remains
relatively unknown.
Taken together, we sought to
investigate the relationship between hmga1
expression and treatment with EF24, with two
specific questions in mind. How does hmga1
expression change upon treatment with EF24?
How do HCT116 cells respond to treatment
with EF24? It was shown that upon treatment
with low-dose, continuous EF24, hmga1
expression was down-regulated. Furthermore,
cell viability decreased significantly upon
treatment with both continuous and pulsed
EF24. Lastly, at low concentrations of EF24,
there was evidence of apoptosis, whereas at

higher concentrations there was increased
evidence of senescence. Further investigation
into this nexus could lead to the discovery of a
viable, targeted combination cancer therapy.

METHODS
Cell Culture
The HCT116 human colon cancer cell
line was obtained from the American Type
Culture Collection (ATCC). Cells were
maintained in McCoy’s 5A media supplemented
with 10% fetal bovine serum and 1% PenicillinStreptomycin-Amphotericin B. Cells were
maintained in a humidified incubator at 37°C
and 5% CO2.
RNA Extraction and RT-PCR
HCT116 cells were treated with varying
concentrations of EF24 (0.0, 0.25, 0.5 M) for
24h. After 24h, total RNA was isolated using
the QuickRNA Mini Prep kit following the
manufacturer’s instructions. GAPDH was used
as a positive control. The forward and reverse
primers for both HMGA1 and GAPDH are
shown below:
Primer
Sequence
HMGA- Forward
5’- GAT GGG ACT
GAG AAG CGA-3’
HMGA1-Reverse
5’-CTT CTC CAG TTT
CTT GGG TC-3’
GAPDH- Forward
5’-TGC ACC ACC
AAC TGC TTA GC-3’
GAPDH-Reverse
5’-GGC ATG GAC
TGT GGT CAT GAG3’
The assembled reactions were run using the
following thermal cycler program:
Temperature
Time
# of cycles
(°C)
50
15 min
1
95
15 min
1
95
20 s
55
30 s
25
72
1 min
72
5 min
1
Cell Viability MTS Assay
Approximately 6000 cells were plated
per well in a 96-well plate, and were incubated
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for 24h. Cells were then treated with increasing
concentrations of EF24 for 24h. For continuous
treatment, the treated cells were assayed for cell
viability following 24h EF24 treatment using
CellTiter Aqueous One Solution Cell
Proliferation Assay. For pulsed treatment, the
treated media was removed, replaced with drugfree media and cells were incubated for an
additional 48h. Following the 48h recovery, cells
were assayed for cell viability. Cell viability was
quantified by measuring absorbance at 490nm.
Apoptosis Assay
HCT116 cells were plated in a 6-well
plate and treated with increasing EF24
concentrations (0.0, 0.05, 0.125 M) for 24h.
Treated media was then removed, and cells were
cultured in drug-free media for an additional
48h. Genomic DNA was then isolated and the
fragments were resolved on a stained agarose
gel.
SA--galactosidase Activity Senescence Assay
Approximately 10,000 cells were plated
per well in a 6-well plate and incubated for 24h.
Cells were then treated with increasing
concentrations of EF24 (0.0, 0.05, 0.125 M)
and incubated for 24h. Treated media was
removed and replaced with drug free media and
incubated for an additional 48h. Cells were lysed
and galactosidase activity was assayed using
the 96-well Cellular Senescence Assay Kit (Cell
Biolabs Inc.) Enzyme activity was quantified by
measuring absorbance at 360nm.

Relative Expression
of HMGA
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Figure 1. HMGA1 mRNA Levels in HCT116 Cells
Treated with Low-Dose EF24 are Down-Regulated
Quantitative real time RT-PCR shows HMGA1 mRNA
levels in treated HCT116 cells are significantly downregulated when compared to untreated cells (p<0.05)

Continuous EF24 Treatment Decreases Cell Survival
The HMGA1 is a key player in
oncogenic transformation because it allows cells
to ignore normal growth pathways and cell cycle
regulations, resulting in abnormal proliferation.
Upon observing that treatment with EF24
resulted in a down-regulation of hmga1, we
decided to test for cell viability after a
continuous 24h treatment. Figure 2 indicates
that there was a significant decrease in cell
viability from 100% to approximately 65% at
low doses of EF24. With a gradual decrease in
cell viability as the concentration of EF24
increases.

Percent Survival (%)

100

RESULTS
EF24 Treatment Down-Regulates hmga1 Expression
HMGA1 has a well-established link to
the phenotype of colon cancer cells. Therefore,
we initially analyzed the effect EF24 treatment
had on hmga1 expression. Treatment with EF24
had a significant effect on the expression of
hmga1 in HCT116 cells. As the concentration of
EF24 increased, the expression of the gene was
three to four-fold down regulated (Figure 1).
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Figure 2. HCT116 Cells Treated with Continuous
Low-Dose EF24 Experienced Decreased Cell
Survival Cell proliferation assays showed treated
HCT116 cells were significantly less viable when
compared to untreated cells (p<0.05)
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Pulsed EF24 Treatment Decreases Cell Survival and
Induces Apoptosis
Chemotherapeutic treatment follows a
treatment-recovery model. Patients undergo
treatment for a period, which is then directly
followed by a period of recovery. We sought to
mimic that model by allowing the cells to
recover post-treatment. Figure 3A indicates
that there was a significant decrease in cell
viability from 100% to 15% at low doses of
EF24. Cell viability was noticeably low across
the board, indicating that cells were unable to
recover after the treated media was removed
regardless of EF24 concentration.
The prominent decrease in cell viability
prompted the need to observe the mechanism
by which the cells were dying, particularly at low
doses. DNA isolated from untreated cells and
from cells treated with 0.05 M EF24 presented
with fragmented DNA. Contrastingly, cells
treated with 0.125M presented with solely
whole DNA (Figure 3B).

Increased Concentrations of EF24 Induce Senescence
It has been shown that curcumin, the
naturally occurring counterpart of EF24, has the
capacity to force cells into a protective process
known as senescence. The absence of
fragmented DNA upon treatment with higher
concentrations of EF24 leads us to believe that
the cells may have been forced out of the cell
cycle into cellular senescence. Figure 4 is
indicative of an increase in senescence
associated -galactosidase activity from
untreated to treated. However, the difference in
activity was not found to be statistically
significant.
Specific Activity of b-gal
(RFU/mg of protein)
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Figure 4. HCT116 Cells Treated with Pulsed LowDose
EF24
Exhibited
Increased
SA-galactosidase Activity SA--galactosidase assays
showed that enzymatic activity increased as
concentration of EF24 treatment increased. However,
results were not statistically significant.

DISCUSSION
HMGA1 is overexpressed in a variety
of different malignant tumors (Scala et al., 2000).
Not only does it facilitate the neoplastic
transformation of normal cells, it also facilitates
drug resistance and abandonment of the cell
cycle
while
simultaneously
inhibiting
programmed cell death (Xu et al., 2004;
D’Angelo et al., 2014; and Fedele et al., 2001).
Recent studies have shown that HMGA1 also
plays a role in the promotion of cellular
senescence (Narita et al, 2006). The present
study investigated the relationship between
HMGA1 expression and EF24 in colon cancer
cells. The data indicates that treatment with
EF24 significantly decreases cell viability at lowdoses and down-regulates hmga1 expression.
Furthermore, upon pulsed treatment with low

Figure 3. HCT116 Cells Treated with Pulsed LowDose EF24 Experienced Apoptosis (A) Cell viability
assays show that there was a significant decrease in cell
viability between treated cells and untreated cells
(p<0.05) (B) Isolated DNA from treated cells was
resolved to show the presence of fragments.
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doses, both apoptotic and senescent activity are
exhibited.
As previously mentioned, expression of
hmga1 results in the inhibition of p53 mediated
apoptosis (Fedele et al., 2001). Therefore, it
follows that upon treatment with therapeutic
agent, EF24, hmga1 expression should decrease.
This hypothesis was confirmed by PCR analysis.
Upon down-regulation of hmga1, the normal cell
cycle should resume resulting in a decrease in
overall cell viability. This trend is observed in
the cells treated with continuous EF24.
Therefore, EF24 is effective in reducing the
viability of colon cancer cells as a first wave
attack. However, this model of treatment does
not accurately represent most modern
chemotherapy treatments.
Chemotherapy follows a treatmentrecovery model. Patients are treated for a short
period of time and allowed to recover. This
method is employed as a means of protecting
non-malignant cells from repetitive attack by
harmful chemotherapeutic drugs. Therefore, an
optimal chemotherapeutic compound should
not continue to kill cells during the recovery
period. Doing so would put vital stem cells at
risk of being compromised. Keeping this in
mind, the colon cancer cells were treated with
EF24 using a pulsed treatment model. The
results indicated that cell viability decreased
significantly despite the 48-hour recovery
period. This prompted us to investigate exactly
what was happening to the cells to compromise
their viability. The apoptosis assay showed
evidence of fragmented DNA in both the
untreated cells and cells that were treated with
the lowest concentration of EF24. However, at
higher concentrations, the band that was
indicative of fragmented DNA disappears.
Taken together with the data from the
senescence assay leads us to postulate that at
higher, pulsed concentrations, cells forego the
apoptotic pathway in favor of the protective
cellular senescence pathway. When cells are
continuously treated with drugs, some will die
and some will enter senescence (Childs et al.,
2014). However, the 24-hour treatment time
might not be long enough to allow the
senescent cells to signal neighboring cells to
enter senescence. Contrastingly, when cells are

treated using a pulsed regimen, the cells that
have entered senescence can continue to signal
neighboring cells even after the treated media is
removed resulting in the drastic decrease in cell
viability observed in Figure 3A.
Continuing to study the role of
HMGA1 in the cellular response of colon
cancer following treatment with EF24 may
contribute to the discovery and development of
less toxic combination cancer therapies.

FUTURE WORK
To confirm the hypothesis that
treatment using a pulsed regimen promotes
cellular senescence, both apoptosis and
senescence assays need to be conducted using
cells that have been treated with a continuous
treatment
model.
Furthermore,
hmga1
expression studies need to be done using cells
treated with a pulsed treatment model.
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